San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor inside the weight loss drug industry in February after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection and in March the